MediWound
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
42 Hayarkon St, Yavne, Central District,...Phone Number
+972 779714100Website
www.mediwound.comRevenue
$17 MillionStock Symbol
MDWDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About MediWound
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutics based on its patented proteolytic enzyme technology that addresses unmet needs in the fields of severe burns, chronic, and other hard-to-heal wounds. MediWound was founded in 2001 and is based in Israel.Explore more
MediWound Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MediWound your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if MediWound had a recent Job posting/layoffs
Product Launch: Get notified when MediWound launches new products
Earning: See what the market has to say on MediWound recently announced quarterly report
MediWound, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at MediWound
Check out if MediWound is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if MediWound has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once MediWound has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
MediWound is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MediWound is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MediWound.
MediWound financials insights
Gather financial insights about MediWound, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$70M
2022
Unspecified
$9M
2023
Other Financing Round
$6.7M
MediWound Tech Stack
A closer look at the technologies used by MediWound
Most Recent Scoops
Earnings
MediWound has reported revenue of ISR 4.6 million for H1 2026, compared with ISR 9.7 million in H1 2025, primarily reflecting the timing of BARDA-funded development revenue, with gross profit of ISR 0.7 million representing a gross margin of 14.4%, compared with ISR 2.1 million and 21.5% in the prior year period.
Earnings, Accounting, Financial Reporting, Finance
Project
MediWound has reported two key upcoming milestones for the EscharEx VALUE Phase III trial: a pre-specified interim sample size reassessment and completion of enrollment, both expected by the end of Q1 2027.
Clinical Operations
Project
MediWound has announced plans to initiate a Phase II diabetic foot ulcer study in Q4 2026, enrolling 50 patients in a randomized, one-to-one design of NexoBrid versus placebo, with time to complete debridement as the primary endpoint, following constructive discussions and protocol alignment with the FDA and EMA.
Pharmaceuticals, Clinical Operations
Earnings
MediWound has reported approximately ISR 36 million in cash equivalents and deposits as of June 2026, compared with ISR 54 million at year-end 2025, with cash burn of ISR 20 million during H1 2026 and ISR 0.8 million generated from warrant and option exercises during the period.
Earnings, Business Finance, Finance
Earnings
Earnings, Research & Development, Finance
MediWound News & Media
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
MediWound Ltd. (MDWD) Q2 2026 Earnings Call August 13, 2026 8:30 AM EDTCompany ParticipantsOfer Gonen - Chief Executive OfficerHani Luxenburg - Chief...MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027MediWound to Report Second Quarter 2026 Financial Results
MediWound to Report Second Quarter 2026 Financial ResultsMediWound Q1 Earnings Call Highlights
MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs. On the company’s earnings call, Chief Executive Officer Ofer G
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MediWound
Sign Up For FreeTo access detailed company insights
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutics based on its patented proteolytic enzyme technology that addresses unmet needs in the fields of severe burns, chronic, and other hard-to-heal wounds. MediWound was founded in 2001 and is based in Israel.... Read More
